Via Scoop.it – OphthalmologySecond Sight Wins 2011 World Technology Award. Argus II is Second Sight’s less invasive second generation implantable device intended to treat blind people suffering from degenerative diseases of the outer retina such as…Via www.marketwatch.com
Author: jfg@linkoph.com
Lucentis receive DME approval in EU
(Ophtalmology Times Europe) Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME). Full Story ->
Selective Laser Trabeculoplasty and Medications: Best Clinical Practices Part 2 of 2
Full Story →
Opinion: Use of a target IOP range in glaucoma management
Full Story →
Nocturnal pressure: the sleeping giant
Full Story →
Deciding when to treat glaucoma, and what to tell patients
Full Story →
The value of diurnal IOP measurement
Full Story →
New imaging techniques in the early diagnosis of glaucomatous optic nerve damage
Full Story →
New technology for the treatment of open-angle glaucoma
Full Story →
Current thinking about glaucoma, target IOP, and the management of surgical complications
Full Story →
News about medical therapy to reduce intraocular pressure
Full Story →
A case study of progressive primary open angle glaucoma
Full Story →